SPCO yields 20.84% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 2
Combined, SPCO + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SPCO + ABBV for your $10,000?
The Stephan Co., together with its subsidiaries, manufactures, sells, and distributes hair care and personal care products. It operates in two segments, Distributors and Brands. The Distributors segment sells to distributors that purchase company's hair care products, and beauty and barber supplies for resale to salons, barbershops, and beauty schools, as well as operates as a mail order, and online barber and beauty supply company. This segment also sells products directly to cosmetology schools. The Brands segment manufacture and sells products to mass merchandisers, chain drug stores, and supermarkets that sells hair care and other personal care products directly to the end user; and distributors that sell to retailers. The company manufactures Image and Sorbie hair care products that are sold through distributors to salons; and Cashmere Bouquet talc, Quinsana Medicated talc, Balm Barr and Stretch Mark creams and lotions, Protein 29 liquid and gel grooming aids, and Stiff Stuff and Wildroot hair care products. It also markets a line of cosmetics through online and mail order channels; and manufactures and sells shampoos, hair treatments, after-shave lotion, dandruff lotion, hair conditioners, and hair spray under the brand name STEPHAN'S, as well as Lekari, New Era, OLD 97, and Imágen. In addition, it markets Hope, Interlude, and Fade-away brand names through various retail chains. The company operates in the United States, Canada, Europe, and Asia. The Stephan Co. was founded in 1897 and is headquartered in Williamsport, Pennsylvania.
Full SPCO Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.